Sagimet Biosciences Suspends And Terminates August 14 Prospectus Supplement Regarding ATM Sales Agreement With Leerink
Effective September 30, 2026, the Company suspended and terminated the prospectus supplement (the "ATM Prospectus Supplement") related to the Company’s Series A common stock, par value $0.0001 per share (the
Sagimet stopped a plan to sell shares through a partner called Leerink. This means the company is changing how it might raise money in the future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.